Cantabio Pharmaceuticals, Inc - CTBO

Cantabio Pharmaceuticals, Inc., a preclinical stage biotechnology company, focuses on the research, development, and commercialization of novel therapies for Parkinson’s disease (PD), Alzheimer’s disease (AD), and other related diseases. Its lead programs include CB101, a DJ-1 targeting small molecule pharmacological chaperone for PD; CB201, a CNS penetrant engineered DJ-1 protein for PD; CB301, a targeting small molecule pharmacological chaperone; and CB401, an Aß targeting small molecule pharmacological chaperone for AD. The company was founded in 2009 and is based in Sunnyvale, California.